author-photo

Tae-You Kim

Seoul National University
Seoul National University Hospital

466

Papers

12741

Citations

Citation Trend

Filter By

Papers (344) Sort By

Journal Conference Others

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Direct Detection of Low Abundance Genes of Single Point Mutation.

2021 Nano Letters
Show All
- Source
- Cite
- Save
Citations (0)
P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.

2021 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (0)
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

2021 Liver International
Show All
- Source
- Cite
- Save
Citations (0)
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.

2021 The Lancet Gastroenterology & Hepatology
Show All
- Source
- Cite
- Save
Citations (3)
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Mutational impact and signature of ionizing radiation

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (1)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (77)